Revised GAAP earnings guidance for AbbVie Inc for the Financial Year ending December 31, 2014 and Third Quarter ending September 30, 2014; Confirms Adjusted Earnings Guidance

For the full-year 2009, Abbott is forecasting global HUMIRA operational sales growth of 25 to 30 percent, excluding the negative impact of exchange, and global HUMIRA reported

Specified items impacted results as follows: 4Q14 Earnings As reported GAAP Adjusted for specified items: Other revenue Intangible asset amortization Acquired IPR&D Calico

"AbbVie" NYSE / CHX / Euronext Paris / SIX: ABBV today informs its stockholders that it is holding the 2015 Annual Meeting of Stockholders of AbbVie on Friday, May 8, 2015 at 9 AM CT

THE TENDER OFFER MATERIALS INCLUDING AN OFFER TO EXCHANGE, A RELATED LETTER OF TRANSMITTAL AND CERTAIN OTHER TENDER OFFER DOCUMENTS AND THE SOLICITATION/RECOMMENDATION STATEMENT

As reported GAAP Adjusted for specified items: Intangible asset amortization Separation costs R&D Acquired IPR&D Calico collaboration Shire transaction costs Other As

- Reports Second-Quarter Adjusted EPS of $0.82, Above Previous Guidance Range of $0.75 to $0.77 Reports GAAP EPS of $0.68 - Delivers Second-Quarter Revenue of $4.926 Billion,

Disclosure requirements of the Takeover Code Under Rule 8.3a of the Takeover Code, any person who is interested in 1% or more of any class of relevant securities of an offeree

Disclosure requirements of the Code Under Rule 8.3a of the Code, any person who is interested in 1% or more of any class of relevant securities of an offeree company or of